# EDGAR Filing Document

**Accession Number:** 0001604191
**File Stem:** 0001104659-25-065274
**Filing Date:** 2025-7
**Character Count:** 7563
**Document Hash:** 106b59cacbb8e002a2b9bfad8dc5e3ae
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-065274.hdr.sgml**: 20250702

**ACCESSION NUMBER**: 0001104659-25-065274

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250630

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250702

**DATE AS OF CHANGE**: 20250702

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Entero Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001604191
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464993860
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37853
- **FILM NUMBER:** 251100891

**BUSINESS ADDRESS:**
- **STREET 1:** 777 YAMATO ROAD
- **STREET 2:** SUITE 502
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431
- **BUSINESS PHONE:** 561-589-7020

**MAIL ADDRESS:**
- **STREET 1:** 777 YAMATO ROAD
- **STREET 2:** SUITE 502
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** First Wave BioPharma, Inc.
- **DATE OF NAME CHANGE:** 20210921

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AzurRx BioPharma, Inc.
- **DATE OF NAME CHANGE:** 20141103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioPharma d'Azur, Inc.
- **DATE OF NAME CHANGE:** 20140331

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 30, 2025**

---

| |
|:---|
| **Entero Therapeutics, Inc.** |
| **(Exact name of registrant as specified in its charter)** |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37853** | **46-4993860** |
| (State or other jurisdiction of<br> incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **777 Yamato Road, Suite 502**<br> **Boca Raton, Florida** | **33431** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (561) 589-7020**

**<u>Not Applicable</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which<br> registered |
| Common Stock, par value $0.0001 per share | ENTO | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

One June 30, 2025, at the 2025 Annual Meeting of Stockholders (the "Annual Meeting") of Entero Therapeutics, Inc. (the "Company"), the stockholders voted on the five proposals listed below and approved each proposal. The proposals are described in detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on June 4, 2025 (the "Proxy Statement"). The final results for the votes regarding each proposal are set forth below.

&nbsp;&nbsp;&nbsp;&nbsp;1. The stockholders elected each of Edward J. Borkowski, Richard Paolone, Eric Corbett, Manpreet Uppal and
Jack Syage to serve on the Company's board of directors for a term of one year expiring at the annual meeting of stockholders to
be held in 2026 or until their respective successors are duly elected and qualified. The tabulation of votes with respect to the election
of such directors was as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Nominees** | **Votes For** | **Votes Withheld** | **Broker Non-Votes** |
| Edward J. Borkowski | 469379 | 38279 | 1328218 |
| Richard Paolone | 450118 | 57540 | 1328218 |
| Eric Corbett | 450123 | 57535 | 1328218 |
| Manpreet Uppal | 449544 | 58114 | 1328218 |
| Jack Syage | 434283 | 73375 | 1328218 |

---

&nbsp;&nbsp;&nbsp;&nbsp;2. The stockholders voted to approve the adoption and approval of an amendment to our Amended and Restated
Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding shares of Common Stock, at a specific
ratio, ranging from 1:2 to 1:20, at any time prior to the one-year anniversary date of the Annual Meeting, with the exact ratio to be
determined by the Board without further approval or authorization of our stockholders. The tabulation of votes with respect to this proposal
was as follows:

---

| | | |
|:---|:---|:---|
| **Vots For** | **Votes Aginst** | **Abstension** |
| 1491305 | 338151 | 6420 |

---

&nbsp;&nbsp;&nbsp;&nbsp;3. The stockholder voted to approve, on an advisory basis, the executive compensation of the Company's
named executive officers as described in the Proxy Statement. The tabulation of votes with respect to this proposal was as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Vots For** | **Votes Aginst** | **Abstension** | **Broker Non-Votes** |
| 415176 | 77434 | 15048 | 1328218 |

---

&nbsp;&nbsp;&nbsp;&nbsp;4. The stockholders voted to approve the ratification of the appointment of Machias Gini & O'Connell
LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025.
The tabulation of votes with respect to this proposal was as follows:

---

| | | |
|:---|:---|:---|
| **Vots For** | **Votes Aginst** | **Abstension** |
| 1697355 | 124752 | 13769 |

---

&nbsp;&nbsp;&nbsp;&nbsp;5. The stockholders approved the adjournment of the Annual Meeting to the extent that there were insufficient
proxies at the Annual Meeting to approve any one or more of the foregoing proposals. The tabulation of votes with respect to this proposal
was as follows:

---

| | | |
|:---|:---|:---|
| **Vots For** | **Votes Aginst** | **Abstension** |
| 1604274 | 225916 | 5686 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Entero Therapeutics, Inc.** | **Entero Therapeutics, Inc.** |
| July 2, 2025 | By: | */s/ Richard Joel Paolone* |
|  | Name: | Richard Joel Paolone |
|  | Title: | Interim Chief Executive Officer |

---